1
|
Laurens B, Planche V, Cubizolle S, Declerck L, Dupouy S, Formaglio M, Koric L, Seassau M, Tilikete C, Vighetto A, Ceccaldi M, Tison F. A Spatial Decision Eye-Tracking Task in Patients with Prodromal and Mild Alzheimer’s Disease. J Alzheimers Dis 2019; 71:613-621. [DOI: 10.3233/jad-190549] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Affiliation(s)
- Brice Laurens
- Université de Bordeaux, CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France
- CHU de Bordeaux, Centre Mémoire de Ressources et de Recherches, Pôle de Neurosciences Cliniques, Bordeaux, France
| | - Vincent Planche
- Université de Bordeaux, CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France
- CHU de Bordeaux, Centre Mémoire de Ressources et de Recherches, Pôle de Neurosciences Cliniques, Bordeaux, France
| | - Stéphanie Cubizolle
- Université de Bordeaux, CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France
| | - Léa Declerck
- Université de Bordeaux, CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France
| | - Sandrine Dupouy
- Université de Bordeaux, CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France
- CHU de Bordeaux, Centre Mémoire de Ressources et de Recherches, Pôle de Neurosciences Cliniques, Bordeaux, France
| | - Maïté Formaglio
- Département de Neurologie cognitive et de Neuro-ophtalmologie, Université Lyon 1 et Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Bron, France
| | - Lejla Koric
- Département de Neurologie et de Neuropsychologie, Aix Marseille Université, Assistance Publique des Hôpitaux de Marseille, Marseille, France
| | | | - Caroline Tilikete
- Département de Neurologie cognitive et de Neuro-ophtalmologie, Université Lyon 1 et Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Bron, France
| | - Alain Vighetto
- Département de Neurologie cognitive et de Neuro-ophtalmologie, Université Lyon 1 et Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Bron, France
| | - Mathieu Ceccaldi
- Département de Neurologie et de Neuropsychologie, Aix Marseille Université, Assistance Publique des Hôpitaux de Marseille, Marseille, France
| | - Françcois Tison
- Université de Bordeaux, CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France
- CHU de Bordeaux, Centre Mémoire de Ressources et de Recherches, Pôle de Neurosciences Cliniques, Bordeaux, France
| |
Collapse
|
2
|
Perez-Lloret S, Negre-Pages L, Damier P, Delval A, Derkinderen P, Destée A, Meissner WG, Tison F, Rascol O. L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey. Eur J Neurol 2017; 24:1532-1538. [PMID: 28940893 DOI: 10.1111/ene.13466] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2017] [Accepted: 09/18/2017] [Indexed: 12/11/2022]
Abstract
BACKGROUND AND PURPOSE Studies assessing the correlations between L-DOPA-induced dyskinesias (LIDs) and motor fluctuations with health-related quality of life (HRQoL) in Parkinson's disease (PD) have yielded conflicting results. This study aimed to assess the relationship between LIDs and motor fluctuations with HRQoL in patients with PD, and to assess the relative contribution of their severity and duration in a large sample of patients with PD. METHODS A total of 683 patients with PD from the COPARK survey were evaluated. HRQoL was assessed using the 39-Item Parkinson's Disease Questionnaire (PDQ-39) (primary outcome) and 36-Item Short Form Survey (SF-36). The daily duration and severity of LIDs were obtained from Unified Parkinson's Disease Rating Scale (UPDRS) IV items 32 and 33, respectively. The daily duration of motor fluctuations was obtained from UPDRS IV item 36 and severity was estimated as the difference between the UPDRS 2 (Activities of Daily Living) score in 'OFF' versus 'ON' condition. RESULTS A total of 235 patients with PD (35%) experienced motor fluctuations and 182 (27%) experienced LIDs. The PDQ-39 total and SF-36 physical scores were significantly worse in patients with LIDs, after adjusting for the presence of motor fluctuations. The PDQ-39 total score and SF-36 physical and mental score were significantly worse in patients with motor fluctuations, after adjusting for the presence of LIDs. The severity of LIDs and the duration of motor fluctuations significantly and independently affected PDQ-39 scores. The SF-36 physical score was affected only by the severity of motor fluctuations, whereas the mental score was not affected by any of the aforementioned variables. CONCLUSION Our findings suggest that LIDs (mainly their severity) and motor fluctuations (mainly their duration) correlate independently with HRQoL in patients with PD.
Collapse
Affiliation(s)
- S Perez-Lloret
- INSERM, Services de Pharmacologie Clinique et Neurosciences, Centre d'Investigation Clinique CIC 1436, NS-Park/FCRIN Network, NeuroToul COEN Center, Université de Toulouse UPS, CHU de Toulouse, Toulouse, France.,Institute of Cardiology Research, University of Buenos Aires, National Research Council (CONICET-ININCA), Buenos Aires, Argentina
| | - L Negre-Pages
- LN Pharma, Toulouse.,Département d'Information Médicale, Unité de Recherche Clinique et Epidémiologie, Hôpital la Colombière, Montpellier
| | - P Damier
- Department of Neurology, INSERM, NS-Park/FCRIN Network, Université de Nantes, CHU de Nantes, Nantes
| | - A Delval
- Department of Neurology, INSERM, NS-Park/FCRIN Network, Université de Lille, CHU de Lille, U 837 Eq6, Lille
| | - P Derkinderen
- Department of Neurology, INSERM, NS-Park/FCRIN Network, Université de Nantes, CHU de Nantes, Nantes
| | - A Destée
- Department of Neurology, INSERM, NS-Park/FCRIN Network, Université de Lille, CHU de Lille, U 837 Eq6, Lille
| | - W G Meissner
- CNRS, CHU de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Service de Neurologie, NS-Park/FCRIN Network, Université de Bordeaux, Bordeaux, France
| | - F Tison
- CNRS, CHU de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Service de Neurologie, NS-Park/FCRIN Network, Université de Bordeaux, Bordeaux, France
| | - O Rascol
- INSERM, Services de Pharmacologie Clinique et Neurosciences, Centre d'Investigation Clinique CIC 1436, NS-Park/FCRIN Network, NeuroToul COEN Center, Université de Toulouse UPS, CHU de Toulouse, Toulouse, France
| | | |
Collapse
|
3
|
Blin P, Rouyer M, Guiard E, Zerbib F, Diquet B, Mégraud F, Tison F, Abouelfath A, Lassalle R, Droz-Perroteau C, Moore N. Conditions d’utilisation en vie réelle du Pylera ® en France à partir des données de l’assurance maladie. Rev Epidemiol Sante Publique 2017. [DOI: 10.1016/j.respe.2017.04.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
4
|
Dujardin K, Auzou N, Lhommée E, Czernecki V, Dubois B, Fradet A, Maltete D, Meyer M, Pineau F, Schmitt E, Sellal F, Tison F, Vidal T, Azulay JP, Welter ML, Corvol JC, Durif F, Rascol O. French consensus procedure for assessing cognitive function in Parkinson's disease. Rev Neurol (Paris) 2016; 172:696-702. [PMID: 27318613 DOI: 10.1016/j.neurol.2016.05.001] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2016] [Accepted: 05/25/2016] [Indexed: 12/11/2022]
Abstract
INTRODUCTION One of the objectives of the French expert centers for Parkinson's disease (NS-Park) network was to determine a consensus procedure for assessing cognitive function in patients with Parkinson's. This article presents this procedure and briefly describes the selected tests. METHODS A group of 13 experts used the Delphi method for consensus building to define the overall structure and components of the assessment procedure. For inclusion in the battery, tests had to be validated in the French language, require little motor participation, have normative data and be recognized by the international community. Experimental tasks and tests requiring specific devices were excluded. RESULTS Two possibilities were identified, depending on whether an abbreviated or comprehensive assessment of cognitive function was necessary. For an abbreviated assessment, the experts recommended the Montreal Cognitive Assessment (MoCA) as a screening test for cognitive impairment or dementia. For a comprehensive neuropsychological assessment, the experts recommended assessing global efficiency plus the five main cognitive domains (attention and working memory, executive function, episodic memory, visuospatial function and language) that may be impaired in Parkinson's disease, using two tests for each domain. DISCUSSION AND CONCLUSION A common procedure for assessing cognitive function is now available across the French network dedicated to Parkinson's disease, and is recommended for both research and clinical practice. It will also help to promote standardization of the neuropsychological assessment of Parkinson's disease.
Collapse
Affiliation(s)
- K Dujardin
- Université de Lille, Inserm U1171, Degenerative & Vascular Cognitive Disorders, 59000 Lille, France; CHU de Lille, Neurology and Movement Disorders, 59000 Lille, France.
| | - N Auzou
- Institute of Neurodegenerative Disorders, CHU de Bordeaux, 33000 Bordeaux, France; Université de Bordeaux, Psychology Laboratory, EA4139, 33000 Bordeaux, France
| | - E Lhommée
- CHU de Grenoble Alpes, Inserm U1216, 38000 Grenoble, France; Université Grenoble Alpes, Grenoble Institut des Neurosciences (GIN), 38000 Grenoble, France
| | - V Czernecki
- CRICM UMRS 975, Neurology Department, AP-HP, Salpetrière Hospital, 75013 Paris, France
| | - B Dubois
- Université Pierre-et-Marie-Curie, Paris VI, ICM, Inserm UMR_S975, Dementia Research Center (IM2A), Salpêtrière Hospital, 75013 Paris, France
| | - A Fradet
- CHU de Poitiers, Neurology & Neuropsychology, Expert Referent Center of Parkinson Disease, CMRR, 86000 Poitiers, France
| | - D Maltete
- Department of Neurology, Rouen University Hospital, 76031 Rouen, France; Inserm U1073, Rouen Faculty of Medicine, 76031 Rouen, France
| | - M Meyer
- CHU de Nancy, Department of Neurology, 54000 Nancy, France
| | - F Pineau
- Département de Neurologie, Hôpitaux Civils de Colmar, 68000 Colmar, France
| | - E Schmitt
- Université Pierre-et-Marie-Curie, Paris VI, ICM, Inserm UMR_S975, Dementia Research Center (IM2A), Salpêtrière Hospital, 75013 Paris, France; CHU de Poitiers, Neurology & Neuropsychology, Expert Referent Center of Parkinson Disease, CMRR, 86000 Poitiers, France
| | - F Sellal
- Département de Neurologie, Hôpitaux Civils de Colmar, 68000 Colmar, France; Inserm U1118, Université de Strasbourg, 67085 Strasbourg, France
| | - F Tison
- Institute of Neurodegenerative Disorders, CHU de Bordeaux, 33000 Bordeaux, France
| | - T Vidal
- CHU de Clermont-Ferrand, Movement Disorders Centre, 63000 Clermont-Ferrand, France; CHU de Clermont-Ferrand, Resource and Research Memory Centre, 63000 Clermont-Ferrand, France
| | - J-P Azulay
- Neurology and Movement Disorders, Hôpital de la Timone, AP-HM, Institut des Neurosciences de la Timone, Université Aix-Marseille, 13385 Marseille, France
| | | | - J-C Corvol
- Sorbonne Universités, UPMC Université Paris 06, Inserm UMRS-1127, CIC-1422, CNRS UMR-7225, AP-HP, ICM, Hôpital Pitié-Salpêtrière, Département des Maladies du Système Nerveux, 75013 Paris, France
| | - F Durif
- CHU de Clermont-Ferrand, Movement Disorders Centre, 63000 Clermont-Ferrand, France
| | - O Rascol
- Clinical Investigation Center (CIC) 1436, Department of Clinical Pharmacolgy and Neurosciences, Inserm, Toulouse University Hospital, University of Toulouse, 31059 Toulouse, France
| | | |
Collapse
|
5
|
Pavy-Le Traon A, Piedvache A, Perez-Lloret S, Calandra-Buonaura G, Cochen-De Cock V, Colosimo C, Cortelli P, Debs R, Duerr S, Fanciulli A, Foubert-Samier A, Gerdelat A, Gurevich T, Krismer F, Poewe W, Tison F, Tranchant C, Wenning G, Rascol O, Meissner WG. New insights into orthostatic hypotension in multiple system atrophy: a European multicentre cohort study. J Neurol Neurosurg Psychiatry 2016; 87:554-61. [PMID: 25977316 DOI: 10.1136/jnnp-2014-309999] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/07/2014] [Accepted: 04/21/2015] [Indexed: 11/04/2022]
Abstract
OBJECTIVES Orthostatic hypotension (OH) is a key feature of multiple system atrophy (MSA), a fatal progressive neurodegenerative disorder associated with autonomic failure, parkinsonism and ataxia. This study aims (1) to determine the clinical spectrum of OH in a large European cohort of patients with MSA and (2) to investigate whether a prolonged postural challenge increases the sensitivity to detect OH in MSA. METHODS Assessment of OH during a 10 min orthostatic test in 349 patients with MSA from seven centres of the European MSA-Study Group (age: 63.6 ± 8.8 years; disease duration: 4.2 ± 2.6 years). Assessment of a possible relationship between OH and MSA subtype (P with predominant parkinsonism or C with predominant cerebellar ataxia), Unified MSA Rating Scale (UMSARS) scores and drug intake. RESULTS 187 patients (54%) had moderate (> 20 mm Hg (systolic blood pressure (SBP)) and/or > 10 mm Hg (diastolic blood pressure (DBP)) or severe OH (> 30 mm Hg (SBP) and/or > 15 mm Hg (DBP)) within 3 min and 250 patients (72%) within 10 min. OH magnitude was significantly associated with disease severity (UMSARS I, II and IV), orthostatic symptoms (UMSARS I) and supine hypertension. OH severity was not associated with MSA subtype. Drug intake did not differ according to OH magnitude except for antihypertensive drugs being less frequently, and antihypotensive drugs more frequently, prescribed in severe OH. CONCLUSIONS This is the largest study of OH in patients with MSA. Our data suggest that the sensitivity to pick up OH increases substantially by a prolonged 10 min orthostatic challenge. These results will help to improve OH management and the design of future clinical trials.
Collapse
Affiliation(s)
- A Pavy-Le Traon
- Neurology Department, French Reference Center for MSA, University Hospital of Toulouse, Toulouse, France Unité INSERM U 1048 Eq 8, Toulouse, France
| | - A Piedvache
- Faculty of Mathematics, Paul Sabatier University, Toulouse, France
| | - S Perez-Lloret
- Department of Clinical Pharmacology, Clinical Investigation Center CIC 1436, University Hospital of Toulouse, University of Toulouse 3 and INSERM, Toulouse, France Faculty of Medical Sciences, UCA-BIOMED-CONICET, Pontificia Universidad Católica Argentina, Buenos Aires, Argentina
| | - G Calandra-Buonaura
- DIBINEM Alma Mater Studiorum-Università di Bologna, Bologna, Italy IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy
| | - V Cochen-De Cock
- Neurology Department, French Reference Center for MSA, University Hospital of Toulouse, Toulouse, France EuroMov, Laboratoire Movement to Health (M2H), Pôle Sommeil et Neurologie Clinique Beau Soleil, University of Montpellier, Montpellier, France
| | - C Colosimo
- Dipartimento di Neurologia e Psichiatria, Sapienza Università di Roma, Roma, Italy
| | - P Cortelli
- DIBINEM Alma Mater Studiorum-Università di Bologna, Bologna, Italy IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy
| | - R Debs
- Neurology Department, French Reference Center for MSA, University Hospital of Toulouse, Toulouse, France
| | - S Duerr
- Department of Neurology, Medical University, Innsbruck, Austria
| | - A Fanciulli
- Department of Neurology, Medical University, Innsbruck, Austria
| | - A Foubert-Samier
- Centre de référence atrophie multisystématisée, CHU de Bordeaux, Bordeaux, France Service de Neurologie, CHU de Bordeaux, Bordeaux, France Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France
| | - A Gerdelat
- Neurology Department, French Reference Center for MSA, University Hospital of Toulouse, Toulouse, France
| | - T Gurevich
- Movement Disorders Unit, Department of Neurology, Sourasky Medical Center, Tel-Aviv University, Tel Aviv, Israel
| | - F Krismer
- Department of Neurology, Medical University, Innsbruck, Austria
| | - W Poewe
- Division of Neurobiology, Medical University, Innsbruck, Austria
| | - F Tison
- Centre de référence atrophie multisystématisée, CHU de Bordeaux, Bordeaux, France Service de Neurologie, CHU de Bordeaux, Bordeaux, France Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France
| | - C Tranchant
- Neurology department, University Hospital Hautepierre, Strasbourg, France
| | - G Wenning
- Department of Neurology, Medical University, Innsbruck, Austria Division of Neurobiology, Medical University, Innsbruck, Austria
| | - O Rascol
- Neurology Department, French Reference Center for MSA, University Hospital of Toulouse, Toulouse, France Department of Clinical Pharmacology, Clinical Investigation Center CIC 1436, University Hospital of Toulouse, University of Toulouse 3 and INSERM, Toulouse, France
| | - W G Meissner
- Centre de référence atrophie multisystématisée, CHU de Bordeaux, Bordeaux, France Service de Neurologie, CHU de Bordeaux, Bordeaux, France Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France
| | | |
Collapse
|
6
|
Foubert-Samier A, Le-Goff M, Helmer C, Jacqmin-Gadda H, Dartigues F, Amieva H, Tison F. Does cognitive decline in Parkinson's disease start before diagnosis? A population-based study. J Neurol Sci 2015. [DOI: 10.1016/j.jns.2015.08.727] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
7
|
Fernagut PO, Meissner WG, Biran M, Fantin M, Bassil F, Franconi JM, Tison F. Age-related motor dysfunction and neuropathology in a transgenic mouse model of multiple system atrophy. Synapse 2013; 68:98-106. [PMID: 24243499 DOI: 10.1002/syn.21719] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2013] [Accepted: 09/24/2013] [Indexed: 12/25/2022]
Abstract
Multiple system atrophy (MSA) is a neurodegenerative disorder characterized by a progressive degeneration of the striatonigral, olivo-ponto-cerebellar, and autonomic systems. Glial cytoplasmic inclusions (GCIs) containing alpha-synuclein represent the hallmark of MSA and are recapitulated in mice expressing alpha-synuclein in oligodendrocytes. To assess if oligodendroglial expression of human wild-type alpha-synuclein in mice (proteolipid promoter, PLP-SYN) could be associated with age-related deficits, PLP-SYN and wild-type mice were assessed for motor function, brain morphometry, striatal levels of dopamine and metabolites, dopaminergic loss, and distribution of GCIs. PLP-SYN displayed age-related impairments on a beam-traversing task. MRI revealed a significantly smaller brain volume in PLP-SYN mice at 12 months, which further decreased at 18 months together with increased volume of ventricles and cortical atrophy. The distribution of GCIs was reminiscent of MSA with a high burden in the basal ganglia. Mild dopaminergic cell loss was associated with decreased dopamine turnover at 18 months. These data indicate that PLP-SYN mice may recapitulate some of the progressive features of MSA and deliver endpoints for the evaluation of therapeutic strategies.
Collapse
Affiliation(s)
- P O Fernagut
- Institut des Maladies Neurodégénératives, Université de Bordeaux, UMR 5293, F-33000 Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
| | | | | | | | | | | | | |
Collapse
|
8
|
Flabeau O, Meissner W, Ozier A, Berger P, Tison F, Fernagut PO. Variabilité respiratoire et déplétion neuronale sérotoninergique du tronc cérébral dans un modèle murin transgénique d’atrophie multisystématisée. Rev Neurol (Paris) 2013. [DOI: 10.1016/j.neurol.2013.01.295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
9
|
Azulay JP, Derkinderen P, Krystkowiak P, Sangla S, Tison F, Ziegler M, Rerat K. Utilisation de Stalevo® en France en 2012-résultats de la phase initiale l’étude START (Stalevo® : réponse à la titration). Rev Neurol (Paris) 2013. [DOI: 10.1016/j.neurol.2013.01.301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
10
|
Tison F, Rouanet F, Neau-Cransac M, Carles J, Couzigou P. Outcome of liver transplantation in Wilson's disease: A demonstrative case. Parkinsonism Relat Disord 2012; 2:131-5. [PMID: 18591031 DOI: 10.1016/1353-8020(96)00008-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 01/03/1996] [Indexed: 11/19/2022]
Abstract
A Wilson's disease (WD) patient developed a progressive liver cirrhosis and a disabling 'rubral' tremor, despite decoppering therapy, and subsequently underwent orthotopic liver transplantation (OLT). This case illustrates the outcome of OLT in WD, by demonstrating: (a) correction of the metabolic syndrome without further deposition of copper in the transplanted liver, (b) improvement of the neurological condition, (c) concomitant mobilization of copper deposits, as suggested by the fading of the Kayser-Fleischer corneal rings, (d) fading of brain MRI signal abnormalities on T2 weighted images. This case illustrates that OLT can be considered in WD, but only with caution because of the significant morbidity of the procedure.
Collapse
Affiliation(s)
- F Tison
- Department of Neurology, Hôpital Pellegrin, Bordeaux, France
| | | | | | | | | |
Collapse
|
11
|
Foubert-Samier A, Helmer C, Perez F, Le Goff M, Auriacombe S, Elbaz A, Dartigues JF, Tison F. Past exposure to neuroleptic drugs and risk of Parkinson disease in an elderly cohort. Neurology 2012; 79:1615-21. [DOI: 10.1212/wnl.0b013e31826e25ce] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
12
|
Fernagut PO, Tison F. Animal models of multiple system atrophy. Neuroscience 2012; 211:77-82. [DOI: 10.1016/j.neuroscience.2011.09.044] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2011] [Revised: 09/20/2011] [Accepted: 09/20/2011] [Indexed: 10/17/2022]
|
13
|
Lesage S, Condroyer C, Klebe S, Honoré A, Tison F, Brefel-Courbon C, Dürr A, Brice A. Identification of VPS35 mutations replicated in French families with Parkinson disease. Neurology 2012; 78:1449-50. [PMID: 22517097 DOI: 10.1212/wnl.0b013e318253d5f2] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- S Lesage
- Centre de Recherche de l’Institut du Cerveau et de la Moelle épinière, Toulouse, France
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Foubert-Samier A, Maurice S, Hivert S, Guelh D, Rigalleau V, Burbaud P, Cuny E, Meissner W, Tison F. A long-term follow-up of weight changes in subthalamic nucleus stimulated Parkinson's disease patients. Rev Neurol (Paris) 2012; 168:173-6. [DOI: 10.1016/j.neurol.2011.04.006] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2010] [Revised: 03/18/2011] [Accepted: 04/26/2011] [Indexed: 10/16/2022]
|
15
|
Latxague C, Perez F, Tison F. 2.119 AN ALGORITHM FOR THE DIAGNOSIS IN PATIENTS PRESENTING PARKINSONISM AND COGNITIVE DEFICITS IN NEUROLOGICAL AND GERIATRIC PRACTICES. Parkinsonism Relat Disord 2012. [DOI: 10.1016/s1353-8020(11)70491-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
16
|
Schmitt E, Rieu I, Chéreau I, Juphard A, Pereira B, de Chazeron I, Tison F, Rascol O, Defebvre L, Schüpbach M, Houeto J, Durif F, Krack P. 1.069 SELF ASSESSMENT SCALE FOR DOPAMINE DEPENDENT BEHAVIOURS IN PARKINSON'S DISEASE. Parkinsonism Relat Disord 2012. [DOI: 10.1016/s1353-8020(11)70183-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
17
|
Perez-Lloret S, Nègre-Pagès L, Ojero-Senard A, Damier P, Destée A, Tison F, Merello M, Rascol O. Oro-buccal symptoms (dysphagia, dysarthria, and sialorrhea) in patients with Parkinson’s disease: preliminary analysis from the French COPARK cohort. Eur J Neurol 2011; 19:28-37. [DOI: 10.1111/j.1468-1331.2011.03402.x] [Citation(s) in RCA: 64] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
18
|
|
19
|
Payoux P, Brefel-Courbon C, Ory-Magne F, Regragui W, Thalamas C, Balduyck S, Durif F, Azulay JP, Tison F, Blin O, Esquerre JP, Rascol O. Motor activation in multiple system atrophy and Parkinson disease: A PET study. Neurology 2010; 75:1174-80. [DOI: 10.1212/wnl.0b013e3181f4d78f] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
20
|
Perez F, Helmer C, Dartigues JF, Auriacombe S, Tison F. A 15-year population-based cohort study of the incidence of Parkinson's disease and dementia with Lewy bodies in an elderly French cohort. J Neurol Neurosurg Psychiatry 2010; 81:742-6. [PMID: 19965839 DOI: 10.1136/jnnp.2009.189142] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
OBJECTIVE To provide global and age-related incidence over 65 years of Parkinsonian syndromes (PS), Parkinson's disease (PD) and suspected dementia with Lewy bodies (DLB). METHODS A 15-year prospective population-based elderly cohort study in South-Western France (PAQUID). RESULTS Incidences found were: 557.7/100,000 person-years for PS, 263 per 100 000 person-years for PD and 112 per 100,000 person-years for suspected DLB. The incidence of all PS, PD and suspected DLB was greater in men. The age-specific incidence of PD decreased over 85, while that of DLB continuously increased, even in the oldest individuals. CONCLUSIONS The authors provide new data on PD and suspected DLB incidence in a large population-based French cohort of subjects aged over 65 and followed up for 15 years. PD incidence decreased in the oldest old contrary to that of suspected DLB cases and Alzheimer's disease.
Collapse
Affiliation(s)
- F Perez
- Parkinson's Disease and Related Disorders Unit, Department of Clinical Neurosciences, University Hospital, Bordeaux, France
| | | | | | | | | |
Collapse
|
21
|
Barraud Q, Lambrecq V, Forni C, Balzamo E, McGuire S, Hill M, Bioulac B, Bezard E, Tison F, Ghorayeb I. P3.172 Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model. Parkinsonism Relat Disord 2009. [DOI: 10.1016/s1353-8020(09)70736-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
22
|
Negre-Pages L, Perez Lloret S, Damier P, Destee A, Tison F, Sampaio C, Ferreira J, Martinez Martin P, Rascol O. P3.135 Predictive factors for PD progression – preliminary results of PARKMIP/COPARK cohort after 24-months follow up. Parkinsonism Relat Disord 2009. [DOI: 10.1016/s1353-8020(09)70699-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
23
|
Damier P, Destée A, Tison F, Rascol O. Suivi prospectif d’une population de patients parkinsoniens (cohorte CoPark). Rev Epidemiol Sante Publique 2009. [DOI: 10.1016/j.respe.2009.02.068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
24
|
Perez Lloret S, Nègre-Pagès L, Cochen V, Debs R, Damier P, Destée A, Tison F, Rascol O. Hallucinations et rêves animés dans la maladie de Parkinson : données préliminaires de l’étude PARKMIP/COPARK. Rev Epidemiol Sante Publique 2009. [DOI: 10.1016/j.respe.2009.02.164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
25
|
Lesage S, Condroyer C, Lannuzel A, Lohmann E, Troiano A, Tison F, Damier P, Thobois S, Ouvrard-Hernandez AM, Rivaud-Péchoux S, Brefel-Courbon C, Destée A, Tranchant C, Romana M, Leclere L, Dürr A, Brice A. Molecular analyses of the LRRK2 gene in European and North African autosomal dominant Parkinson's disease. J Med Genet 2009; 46:458-64. [PMID: 19357115 DOI: 10.1136/jmg.2008.062612] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND Mutations in the leucine-rich-repeat kinase 2 (LRRK2) gene have been identified in families with autosomal dominant Parkinson's disease (ADPD), the most common of which is the p.G2019S substitution that has been found at varying frequencies worldwide. Because of the size of the LRRK2 gene, few studies have analysed the entire gene in large series of ADPD families. METHODS We performed extensive mutation analyses of all 51 coding exons of the LRRK2 gene in index cases from 226 Parkinson's disease families compatible with autosomal dominant inheritance, mostly from France (n = 182) and North Africa (n = 14). RESULTS We found 79 sequence variants, 29 of which were novel. Eight potentially or proven pathogenic mutations were found in 22 probands (9.7%). There were four novel amino acid substitutions that are potentially pathogenic (p.S52F, p.N363S, p.I810V, p.R1325Q) and two novel variants, p.H1216R and p.T1410M, that are probably not causative. The common p.G2019S mutation was identified in 13 probands (5.8%) including six from North Africa (43%). The known heterozygous p.R1441H and p.I1371V mutations were found in two probands each, and the p.E334K variant was identified in one single patient. Most potentially or proven pathogenic mutations were located in the functional domains of the Lrrk2 protein. CONCLUSION This study leads us to conclude that LRRK2 mutations are a common cause of autosomal dominant Parkinson's disease in Europe and North Africa.
Collapse
|
26
|
Nègre-Pagès L, Cochen V, Debs R, Damier P, Destée A, Tison F, Rascol O. Prévalence et facteurs associés aux hallucinations dans la maladie de Parkinson : données préliminaires de l’étude COPARK dans la Région Midi-Pyrénées (PARKMIP). Rev Neurol (Paris) 2009. [DOI: 10.1016/s0035-3787(09)70003-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
27
|
Krim E, Tison F. Atrofia multisistemica. Neurologia 2009. [DOI: 10.1016/s1634-7072(09)70517-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
28
|
|
29
|
Tison F. [Treatment of later phases of Parkinson disease]. Rev Neurol (Paris) 2008; 164 Spec No 2:F85-F88. [PMID: 18680823] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Affiliation(s)
- F Tison
- Département de neurologie, CHU de Bordeaux, GH Sud, Hôpital Haut-Lévêque, Bordeaux.
| |
Collapse
|
30
|
Lambrecq V, Krim E, Meissner W, Guehl D, Tison F. [Deep-brain stimulation of the internal pallidum in multiple system atrophy]. Rev Neurol (Paris) 2008; 164:398-402. [PMID: 18439935 DOI: 10.1016/j.neurol.2008.01.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2007] [Revised: 09/07/2007] [Accepted: 01/11/2008] [Indexed: 10/22/2022]
Abstract
INTRODUCTION The experience with deep-brain stimulation (DBS) in multiple-system atrophy (MSA) is sparse and generally disappointing. DBS is currently not recommended in MSA and its use is often related to a misdiagnosis. OBSERVATION We describe the outcome of bilateral DBS of the internal pallidum in a 46-year-old woman suffering from MSA that initially resembled Parkinson's disease with prominent levodopa-induced dyskinesias. DBS of the left internal pallidum was performed in 1998 after a ten-year clinical course and improved dyskinesias. Six months later, the right side was implanted. A few months after the second surgery, the patient progressively developed signs of cerebellar and dysautonomic impairment and MSA was diagnosed. CONCLUSION Our observation confirms the ineffectiveness of DBS of the internal pallidum in MSA and even suggests a harmful effect. DBS remains contra-indicated in atypical parkinsonism.
Collapse
Affiliation(s)
- V Lambrecq
- Département de neurologie, groupe hospitalier sud, CHU de Bordeaux, Bordeaux, France
| | | | | | | | | |
Collapse
|
31
|
Kreisler A, Mastain B, Tison F, Fénelon G, Destée A. Infarctus cérébraux multiples se présentant comme une dégénérescence cortico-basale : pseudo dégénérescence cortico-basale vasculaire ? Rev Neurol (Paris) 2007; 163:1191-9. [DOI: 10.1016/s0035-3787(07)78403-5] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
32
|
Lesage S, Lohmann E, Tison F, Durif F, Dürr A, Brice A. Rare heterozygous parkin variants in French early-onset Parkinson disease patients and controls. J Med Genet 2007; 45:43-6. [PMID: 17766365 DOI: 10.1136/jmg.2007.051854] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BACKGROUND Mutations in the parkin gene cause autosomal recessive early-onset parkinsonism. The effect of single heterozygous mutations in parkin is still unclear. The aim of this study was to evaluate the frequency of exonic parkin variants in a case-control study. METHODS The parkin gene was screened for both point mutations and exon rearrangements in 172 French patients with Parkinson disease (PD) and 170 controls from the same population. Patients with single parkin variants were also screened for PINK1, DJ-1 and LRRK2 exon 41 mutations. RESULTS 10 exonic sequence variations were identified, including 3 known polymorphisms and 7 rare heterozygous variants, 2 of which were novel. There were significantly more rare heterozygous variants in patients (n = 10) with early-onset PD than in controls (n = 2). Screening of PINK1, DJ-1 and LRRK2 exon 41 in the 10 patients heterozygous for parkin failed to identify a second causative mutation. CONCLUSION These results suggest that single parkin mutations increase the risk of early-onset PD, but the possibility of a second parkin mutation cannot be excluded.
Collapse
|
33
|
Foubert-Samier A, Krim E, Rigalleauc V, Burbaud P, Tison F. D - 7 Étude prospective des modifications de la charge pondérale chez le parkinsonien neurostimulé. Rev Neurol (Paris) 2007. [DOI: 10.1016/s0035-3787(07)90805-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
34
|
Corcuff JB, Krim E, Tison F, Foubert-Sanier A, Guehl D, Burbaud P, Cuny E, Baillet L, Gin H, Rigalleau V, Perlemoine C. Letters to the Editor. Br J Nutr 2007; 95:1028-9. [PMID: 16611397 DOI: 10.1079/bjn20051678] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
35
|
Guehl D, Cuny E, Tison F, Benazzouz A, Bardinet E, Sibon Y, Ghorayeb I, Yelnick J, Rougier A, Bioulac B, Burbaud P. Deep brain pallidal stimulation for movement disorders in neuroacanthocytosis. Neurology 2007; 68:160-1. [PMID: 17210902 DOI: 10.1212/01.wnl.0000250536.81426.1a] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- D Guehl
- Department of Neurosurgery, Centre Hospitalier Pellegrin, Bordeaux, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Abstract
The term "neuroacanthocytosis" is normally used to refer to autosomal recessive chorea-acanthocytosis and X-linked McLeod syndrome, but there are other movement disorders in which erythrocyte acanthocytosis may also be seen, such as Huntington disease-like 2 and pantothenate kinase-associated neurodegeneration. Disorders of serum lipoproteins such as Bassen-Kornzweig disease form a distinct group of neuroacanthocytosis syndromes in which ataxia is observed, but movement disorders are not seen. Genetic testing has enabled us to distinguish between these disorders, even when there are considerable similarities between phenotypes. Improved detection is important for accurate genetic counseling, for monitoring for complications, and, it is hoped, for implementing causal treatments, once these become available. As in other neurodegenerative conditions, animal models are a promising strategy for the development of such therapies.
Collapse
Affiliation(s)
- R H Walker
- Department of Neurology, James J. Peters Veterans Affairs Medical Center, Bronx, NY 10468, USA.
| | | | | | | | | | | | | |
Collapse
|
37
|
|
38
|
Krim E, Yekhlef F, Chrysostome V, Ghorayeb I, Tison F. Atrophie multisystématisée : survie et facteurs pronostiques dans la cohorte « MSA-Aquitaine ». Rev Neurol (Paris) 2007; 163:54-65. [PMID: 17304173 DOI: 10.1016/s0035-3787(07)90355-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
INTRODUCTION Multiple system atrophy (MSA) is a common cause of atypical parkinsonism, of poor prognosis. MSA is associated with short survival but data stemming from clinical or pathological studies are sparse and contrasted. Factors predicting survival in MSA are not fully established. We investigated the survival and prognostic factors of MSA in the cohort "MSA-Aquitaine". METHODS This was a retrospective study of an unselected cohort of patients included throughout Aquitaine based on the Consensus Conference statement concerning MSA diagnostic criteria, with prospective follow-up on mortality. All patients received a standard clinical examination and disease history was collected through medical records and interviews of patients. Survival was ascertained by telephonic calls. RESULTS From 1 November 1998 to 1 April 2002, we diagnosed 86 patients (43 men and 43 women) with "probable" or "possible" MSA. Median survival from study inclusion was 2.4 years and was 10.2 years from clinical onset, very similar to the other series. Low age at study, diabetes, dysphagia, Hoehn and Yahr stage 5 can predict shorter survival in patients with MSA. CONCLUSION We confirm that the prognosis for MSA patients is poor and that some factors may predict shorter survival.
Collapse
Affiliation(s)
- E Krim
- Département de Neurologie, Groupe Hospitalier Sud, CHU de Bordeaux
| | | | | | | | | |
Collapse
|
39
|
Guehl D, Cuny E, Benazzouz A, Rougier A, Tison F, Machado S, Grabot D, Gross C, Bioulac B, Burbaud P. Side-effects of subthalamic stimulation in Parkinson's disease: clinical evolution and predictive factors. Eur J Neurol 2006; 13:963-71. [PMID: 16930362 DOI: 10.1111/j.1468-1331.2006.01405.x] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Chronic bilateral high-frequency stimulation of the subthalamic nucleus (STN) is an alternative treatment for disabling forms of Parkinson's disease when on-off fluctuations and levodopa-induced dyskinesias compromise patients' quality of life. The aim of this study was to assess the evolution of side-effects during the first year of follow-up and search for clinical predictive factors accounting for their occurrence. We compared the frequency of side-effects at 3 and 12 months after surgery in a cohort of 44 patients. The off-medication scores of Unified Parkinson's Disease Rating Scale (UPDRS) II, III, axial symptoms, disease duration and age at surgery were retained for correlation analysis. Dysarthria/hypophonia, weight gain and postural instability were the most frequent chronic side-effects. Whereas dysarthria/hypophonia remained stable over time, weight gain and postural instability increased during the first year post-op. High axial and UPDRS II scores at surgery were predictive of dysarthria/hypophonia. Age and axial score at surgery were positively correlated with postural instability. Despite the occurrence of side-effects, the benefit/side-effects ratio of STN stimulation was largely positive during the first year of follow-up. Age, intensity of axial symptoms and UDPRS II off-medication score before surgery are predictive factors of dysarthria/hypophonia and postural instability after surgery.
Collapse
Affiliation(s)
- D Guehl
- Service de Neurophysiologie Clinique, Hôpital Pellegrin, Place Amélie-Rabat Léon, Bordeaux, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Abstract
Research into the pathophysiology of Parkinson's disease has been rapidly advanced by the development of animal models. Initial models were developed by using toxins that specifically targeted dopamine neurons, the most successful of which used 6-hydroxydopamine in rats and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice and primates. Their combination with specific striatal toxins, such as quinolinic acid or 3-nitropropionic acid, has led to the development of experimental models replicating the salient pathological and clinical features of multiple system atrophy of the striatonigral degeneration subtype both in rodents and primates. More recently, the identification of alpha-synuclein gene mutations in rare familial cases of Parkinson's disease has led to the development of alpha-synuclein knock-out and transgenic animals. We conclude that the use and improvement of both phenotypic and genetic models can significantly speed progress toward understanding the pathophysiology of these devastating diseases and finding innovative cures.
Collapse
Affiliation(s)
- I Ghorayeb
- Laboratoire de Neurophysiologie, CNRS-UMR 5543, Université Victor-Segalen Bordeaux 2, Bordeaux.
| | | | | | | | | |
Collapse
|
41
|
Guehl D, Dehail P, de Sèze MP, Cuny E, Faux P, Tison F, Barat M, Bioulac B, Burbaud P. Evolution of postural stability after subthalamic nucleus stimulation in Parkinson’s disease: a combined clinical and posturometric study. Exp Brain Res 2005; 170:206-15. [PMID: 16328280 DOI: 10.1007/s00221-005-0202-z] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2004] [Accepted: 08/18/2005] [Indexed: 10/25/2022]
Abstract
OBJECTIVES The occurrence of postural and balance disorders is a frequent feature in advanced forms of Parkinson's disease (PD). However, the pathological substrate of these disturbances is poorly understood. METHODS In the present work, we investigated the evolution of posturometric parameters [center of pressure (CoP) displacement and CoP area] and axial scores between the pre-operative period and 3 months post-operative in seven PD patients who underwent bilateral deep brain stimulation (DBS) of the subthalamic nucleus (STN). RESULTS After surgery, the patients leaned backwards much more regardless of the STN stimulation, suggesting that surgery could have a deleterious effect on postural adaptation. During the post-operative period, the improvement in axial and postural scores was similar under levodopatherapy and DBS. On the other hand, DBS of the STN significantly reduced the CoP displacement and the CoP area, whereas levodopatherapy tended only to reduce the CoP displacement and to increase the CoP area significantly. CONCLUSIONS These data suggest that DBS of the STN and levodopa do not act on the same neurological systems involved in posture regulation. DBS of the STN could improve posture via a direct effect on the pedunculopontine nucleus, which is known to be involved in posture regulation.
Collapse
Affiliation(s)
- D Guehl
- Service de Neurophysiologie Clinique, Hôpital Pellegrin, Place Amélie-Raba-Léon, CNRS UMR 5543, Université de Bordeaux, 2, Victor Segalen, 146 rue Léo Saignat, 33076, Bordeaux, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Abstract
The restless legs syndrome (RLS) is one of the commonest neurological sensorimotor disorders at least in the Western countries and is often associated with periodic limb movements (PLM) during sleep leading to severe insomnia. However, it remains largely underdiagnosed and its underlying pathogenesis is presently unknown. Women are more affected than men and early-onset disease is associated with familial cases. A genetic origin has been suggested but the mode of inheritance is unknown. Secondary causes of RLS may share a common underlying pathophysiology implicating iron deficiency or misuse. The excellent response to dopaminegic drugs points to a central role of dopamine in the pathophysiology of RLS. Iron may also represent a primary factor in the development of RLS, as suggested by recent pathological and brain imaging studies. However, the way dopamine and iron, and probably other compounds, interact to generate the circadian pattern in the occurrence of RLS and PLM symptoms remains unknown. The same is also the case for the level of interaction of the two compounds within the central nervous system (CNS). Recent electrophysiological and animals studies suggest that complex spinal mechanisms are involved in the generation of RLS and PLM symptomatology. Dopamine modulation of spinal reflexes through dopamine D3 receptors was recently highlighted in animal models. The present review suggests that RLS is a complex disorder that may result from a complex dysfunction of interacting neuronal networks at one or several levels of the CNS and involving numerous neurotransmitter systems.
Collapse
Affiliation(s)
- G Barrière
- Laboratoire de Neurophysiologie, UMR-CNRS 5543, Université Bordeaux 2, Bordeaux, France
| | | | | | | | | |
Collapse
|
43
|
Abstract
Complaints about sleep disorders and excessive daytime sleepiness are common among patients with multiple system atrophy. The diffuse neurodegenerative process that encompasses the key structures involved in the regulation of the sleep/wake transition and respiratory function may account for these complaints and for the most frequent polysomnographic findings in MSA, i.e., sleep-related breathing disturbances and REM sleep behaviour disorder, which are both treatable conditions. Nocturnal stridor is an inspiratory sound produced by complex vocal cord muscle dysfunction. Often occurring with sleep apnoea, stridor is associated with decreased survival. REM sleep behaviour disorder, a parasomnia characterized by loss of normal skeletal muscle atonia during REM sleep with prominent motor activity, is detected in almost all patients. The pathophysiology of both disorders is partially elucidated but increasing evidence points to the role of basal ganglia dysfunction.
Collapse
Affiliation(s)
- I Ghorayeb
- Service d'Explorations Fonctionnelles du Système Nerveux, Bordeaux, France.
| | | | | |
Collapse
|
44
|
Geser F, Seppi K, Stampfer-Kountchev M, Köllensperger M, Diem A, Ndayisaba JP, Ostergaard K, Dupont E, Cardozo A, Tolosa E, Abele M, Dodel R, Klockgether T, Ghorayeb I, Yekhlef F, Tison F, Daniels C, Kopper F, Deuschl G, Coelho M, Ferreira J, Rosa MM, Sampaio C, Bozi M, Schrag A, Hooker J, Kim H, Scaravilli T, Mathias CJ, Fowler C, Wood N, Quinn N, Widner H, Nilsson CF, Lindvall O, Schimke N, Eggert KM, Oertel W, del Sorbo F, Carella F, Albanese A, Pellecchia MT, Barone P, Djaldetti R, Meco G, Colosimo C, Gonzalez-Mandly A, Berciano J, Gurevich T, Giladi N, Galitzky M, Ory F, Rascol O, Kamm C, Buerk K, Maass S, Gasser T, Poewe W, Wenning GK. The European Multiple System Atrophy-Study Group (EMSA-SG). J Neural Transm (Vienna) 2005; 112:1677-86. [PMID: 16049636 DOI: 10.1007/s00702-005-0328-y] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2005] [Accepted: 04/30/2005] [Indexed: 11/26/2022]
Abstract
Introduction. The European Multiple System Atrophy-Study Group (EMSA-SG) is an academic network comprising 23 centers across Europe and Israel that has constituted itself already in January 1999. This international forum of established experts under the guidance of the University Hospital of Innsbruck as coordinating center is supported by the 5th framework program of the European Union since March 2001 (QLK6-CT-2000-00661). Objectives. Primary goals of the network include (1) a central Registry for European multiple system atrophy (MSA) patients, (2) a decentralized DNA Bank, (3) the development and validation of the novel Unified MSA Rating Scale (UMSARS), (4) the conduction of a Natural History Study (NHS), and (5) the planning or implementation of interventional therapeutic trials. Methods. The EMSA-SG Registry is a computerized data bank localized at the coordinating centre in Innsbruck collecting diagnostic and therapeutic data of MSA patients. Blood samples of patients and controls are recruited into the DNA Bank. The UMSARS is a novel specific rating instrument that has been developed and validated by the EMSA-SG. The NHS comprises assessments of basic anthropometric data as well as a range of scales including the UMSARS, Unified Parkinson's Disease Rating Scale (UPDRS), measures of global disability, Red Flag list, MMSE (Mini Mental State Examination), quality of live measures, i.e. EuroQoL 5D (EQ-5D) and Medical Outcome Study Short Form (SF-36) as well as the Beck Depression Inventory (BDI). In a subgroup of patients dysautonomic features are recorded in detail using the Queen Square Cardiovascular Autonomic Function Test Battery, the Composite Autonomic Symptom Scale (COMPASS) and measurements of residual urinary volume. Most of these measures are repeated at 6-monthly follow up visits for a total study period of 24 months. Surrogate markers of the disease progression are identified by the EMSA-SG using magnetic resonance and diffusion weighted imaging (MRI and DWI, respectively). Results. 412 patients have been recruited into the Registry so far. Probable MSA-P was the most common diagnosis (49% of cases). 507 patients donated DNA for research. 131 patients have been recruited into the NHS. There was a rapid deterioration of the motor disorder (in particular akinesia) by 26.1% of the UMSARS II, and - to a lesser degree - of activities of daily living by 16.8% of the UMSARS I in relation to the respective baseline scores. Motor progression was associated with low motor or global disability as well as low akinesia or cerebellar subscores at baseline. Mental function did not deteriorate during this short follow up period. Conclusion. For the first time, prospective data concerning disease progression are available. Such data about the natural history and prognosis of MSA as well as surrogate markers of disease process allow planning and implementation of multi-centre phase II/III neuroprotective intervention trials within the next years more effectively. Indeed, a trial on growth hormone in MSA has just been completed, and another on minocycline will be completed by the end of this year.
Collapse
Affiliation(s)
- F Geser
- Clinical Department of Neurology, Innsbruck Medical University, Austria
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Tison F, Crochard A, Léger D, Bouée S, Lainey E, El Hasnaoui A. Epidemiology of restless legs syndrome in French adults: A nationwide survey: The INSTANT Study. Neurology 2005; 65:239-46. [PMID: 16043793 DOI: 10.1212/01.wnl.0000168910.48309.4a] [Citation(s) in RCA: 243] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE To evaluate the prevalence, characteristics, and treatment of restless legs syndrome (RLS) in France. METHODS In this population-based survey, face-to-face home interviews were conducted among a random sample of 10,263 French adults. A French translation of the four features defined by the International RLS Study Group in 1995 was used to assess the prevalence of symptoms consistent with a diagnosis of RLS. Data on severity of symptoms and their management were also collected. RESULTS The 12-month prevalence of RLS symptoms in the French adult population was estimated to be 8.5% (95% CI 8.0%, 9.0%), with a higher prevalence (p < 0.001) observed in women (10.8%) than in men (5.8%). Prevalence increases with age until 64 years and decreases thereafter in both sexes. Half of the identified subjects reported symptoms once a week at least. Symptoms were more severe in subjects reporting symptoms once a week at least compared to subjects with less frequent symptoms. In this group, half of the subjects reported a family history, the age at onset was earlier, and severity of symptoms higher. RLS had been previously diagnosed in only 5.3% of the subjects who reported previous medical diagnosis, and recommended RLS drug treatment was received by 3.4% of the 28.7% currently treated subjects. CONCLUSIONS Restless legs syndrome (RLS) occurred in 10% of women and 5% of men. RLS prevalence decreases after the age of 64. RLS is often underdiagnosed and few subjects receive recommended RLS drug treatment.
Collapse
Affiliation(s)
- F Tison
- Hôpital Haut Levêque, Pessac, France
| | | | | | | | | | | |
Collapse
|
46
|
Scherfler C, Sather T, Diguet E, Stefanova N, Puschban Z, Tison F, Poewe W, Wenning GK. Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy). J Neural Transm (Vienna) 2004; 112:1025-33. [PMID: 15583958 DOI: 10.1007/s00702-004-0245-5] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2004] [Accepted: 10/16/2004] [Indexed: 11/26/2022]
Abstract
We investigated neuroprotective effects of riluzole, an anti-glutamatergic agent that is FDA approved for disease-modifying therapy in amyotrophic lateral sclerosis (ALS), in an established double lesion rat model of striatonigral degeneration (SND), the neuropathological substrate of parkinsonism associated with MSA (MSA-P). Riluzole was administered prior to and consecutively for ten days following double lesion placement in the left-sided medial forebrain bundle and ipsilateral striatum. Assessment of motor behaviour using a flex field system showed a significant reduction of motor disturbance in animals with striatonigral lesions treated with riluzole compared to lesioned but untreated animals (P<0.001). DARPP-32 immunohistochemistry revealed a significant reduction of absolute striatal lesion volume in riluzole treated animals compared to lesioned but untreated animals (P<0.01). No significant difference in counts of nigral dopaminergic neurons was found in treated versus untreated double-lesioned animals. The results of our study indicate that riluzole mediates neuroprotective effects in the double lesion rat model of MSA-P. Whether riluzole also protects autonomic and cerebellar pathways that are frequently affected in MSA remains to be determined. Nonetheless, our study is the first to provide an experimental rationale for exploring possible neuroprotective effects of riluzole in MSA.
Collapse
Affiliation(s)
- C Scherfler
- Department of Neurology, University Hospital, Innsbruck, Austria
| | | | | | | | | | | | | | | |
Collapse
|
47
|
Diguet E, Fernagut PO, Scherfler C, Wenning G, Tison F. Effects of riluzole on combined MPTP + 3-nitropropionic acid-induced mild to moderate striatonigral degeneration in mice. J Neural Transm (Vienna) 2004; 112:613-31. [PMID: 15503195 DOI: 10.1007/s00702-004-0206-z] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2004] [Accepted: 07/16/2004] [Indexed: 10/26/2022]
Abstract
We investigated the potency of riluzole, an anti-glutamatergic drug, to affect ongoing neuronal death process following combined MPTP + 3-nitropropionic acid (3-NP) intoxication producing combined striatal and nigral degeneration (SND) in mice. We used a "neuronal rescue" strategy by administering riluzole after the end of intoxication. The motor disorder, its recovery, behavioral performances at motor and sensorimotor integration tasks and histopathological outcome were compared in the saline and riluzole groups (10 mg/kg and 20 mg/kg), matched by triplets for motor severity. While riluzole did not produce any effect on the gross motor disorder nor on rotarod task, open-field kinetic variables or on the traversing beam task, it had a subtle effect on the performances at the pole test. The histopathological outcome was significantly better in the riluzole-treated mice regarding both nigral and dorsolateral striatal cell loss and astroglial activation, with a dose-effect relationship. Thus, riluzole has limited "neuronal rescue" properties from an histopathological point of view with a subtle motor behavior improvement in a MPTP + 3-NP-induced SND in mice.
Collapse
Affiliation(s)
- E Diguet
- Physiologie et Physiopathologie de la Signalisation Cellulaire, UMR-CNRS 5543, Université Victor Segalen-Bordeaux2, Bordeaux, France
| | | | | | | | | |
Collapse
|
48
|
Ibáñez P, Bonnet AM, Débarges B, Lohmann E, Tison F, Pollak P, Agid Y, Dürr A, Brice A. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 2004; 364:1169-71. [PMID: 15451225 DOI: 10.1016/s0140-6736(04)17104-3] [Citation(s) in RCA: 784] [Impact Index Per Article: 39.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
The alpha-synuclein gene (SNCA) has been implicated in autosomal dominant forms of Parkinson's disease. We screened 119 individuals from families with this rare form of the disease for SNCA duplications by semiquantitative multiplex PCR. Two patients had duplications, which were confirmed by analysis of intragenic and flanking microsatellite markers. The phenotype in both patients was indistinguishable from idiopathic Parkinson's disease and no atypical features were present, by contrast with reports of families with triplication of the same gene. These results indicate that SNCA is more frequently associated with familial Parkinson's disease than previously thought, and that there is a clear dosage effect according to the number of supernumerary copies of this gene.
Collapse
Affiliation(s)
- P Ibáñez
- INSERM U289, Neurologie et Thérapeutique Expérimentale, Hôpital de la Pitié-Salpêtrière, AP-HP, Paris, France
| | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Chrysostome V, Tison F, Yekhlef F, Sourgen C, Baldi I, Dartigues JF. Epidemiology of multiple system atrophy: a prevalence and pilot risk factor study in Aquitaine, France. Neuroepidemiology 2004; 23:201-8. [PMID: 15272223 DOI: 10.1159/000078506] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
We investigated the prevalence of multiple system atrophy (MSA) in Gironde, France, through a network of 120 public and private specialists and assessed the relationship between some environmental factors and MSA in a case-control study involving 50 MSA patients, 50 Parkinson's disease (PD) patients and 50 healthy controls. The occupational exposure to pesticides was evaluated through a job-exposure matrix. On prevalence day (November 1, 1998), the crude prevalence of MSA in Gironde was 1.94/100,000 inhabitants. We found no significant relationship between occupational exposure to pesticides and MSA. PD patients were significantly less frequently ever-smokers than controls and the same tendency was observed for MSA patients. We also described the clinical features that heralded the disease among this nonselected population.
Collapse
Affiliation(s)
- V Chrysostome
- Federation of Neurology, Epidemiology and Biostatistics, Centre Hospitalo-Universitaire de Bordeaux, Bordeaux, France
| | | | | | | | | | | |
Collapse
|
50
|
Stefanova N, Lundblad M, Tison F, Poewe W, Cenci MA, Wenning GK. Effects of pulsatile L-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy). Neurobiol Dis 2004; 15:630-9. [PMID: 15056471 DOI: 10.1016/j.nbd.2003.11.025] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2003] [Revised: 11/07/2003] [Accepted: 11/18/2003] [Indexed: 11/21/2022] Open
Abstract
We examined the role of a striatal lesion in the development of L-DOPA-induced abnormal involuntary movements (AIMs) using the double lesion rat model of striatonigral degeneration (SND), the underlying neuropathological substrate of parkinsonism associated with multiple system atrophy (MSA-P), in comparison to a Parkinson's disease (PD) rat model. L-DOPA administration reliably induced AIMs in SND and PD rats in a dose-dependent fashion. AIMs occurred significantly earlier in SND compared to PD rats. There was a mild, but significant, transient increase of orolingual AIMs during the first week of low-dose L-DOPA treatment in SND. Whereas L-DOPA significantly improved contralateral forelimb akinesia in PD rats, there was no beneficial effect in SND rats. Striatal FosB/Delta FosB up-regulation in SND and PD rats correlated with the severity of L-DOPA-induced dyskinesias. Pulsatile L-DOPA administration in the double lesion SND rat model replicates salient features of the human disease MSA-P, including loss of the anti-akinetic L-DOPA response and induction of dyskinesias with transient orolingual predominance.
Collapse
Affiliation(s)
- N Stefanova
- Department of Neurology, University Hospital of Innsbruck, Innsbruck, Austria
| | | | | | | | | | | |
Collapse
|